introduction: amodiaquine is a partner drug in the artemisinin-based combination therapy artesunate-amodiaquine. reports of the adverse drug reaction known as amodiaquine-associated asthenia are scarce, and this adverse reaction needs to be investigated in detail. this article presents and reviews a case of amodiaquine-associated asthenia. a literature search for the characteristics of this adv...

Abstract The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor T‐cell therapy, tisagenlecleucel, in August 2017. We sought to describe adverse events (AEs) reported FDA Adverse Event Reporting System (FAERS) for tisagenlecleucel post‐marketing period. searched FAERS reports identify patients treated with between 30, 2017‐August 31, 2019. reviewed individual re...

The aim of the present paper is to examine the complex relationship between medication and driving ability from the point o f view of Physicians and Pharmacists responsible for treating patients who drive: that is, choosing the right medication (medically prescribed or over-thecounter), or m odifying treatment accordingly, informing the patient about the prescribed drug or drugs, dispensing the...

BrAIed7 1990;300:82-3 Naproxen, phenylbutazone, sulindac, tolfenamic acid, and glafenine are the only non-steroidal anti-inflammatory drugs that have been implicated in the development ofan allergic pulmonary eosinophilia. 4I describe four cases in which fenbufen was associated with the development of rash and pulmonary eosinophilia. The Committee on Safety of Medicines was notified of all case...